دورية أكاديمية
أعرض في EDS

Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.

التفاصيل البيبلوغرافية
العنوان: Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.
المؤلفون: Pearce CL; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. cpearce@usc.edu, Near AM, Van Den Berg DJ, Ramus SJ, Gentry-Maharaj A, Menon U, Gayther SA, Anderson AR, Edlund CK, Wu AH, Chen X, Beesley J, Webb PM, Holt SK, Chen C, Doherty JA, Rossing MA, Whittemore AS, McGuire V, DiCioccio RA, Goodman MT, Lurie G, Carney ME, Wilkens LR, Ness RB, Moysich KB, Edwards R, Jennison E, Kjaer SK, Hogdall E, Hogdall CK, Goode EL, Sellers TA, Vierkant RA, Cunningham JM, Schildkraut JM, Berchuck A, Moorman PG, Iversen ES, Cramer DW, Terry KL, Vitonis AF, Titus-Ernstoff L, Song H, Pharoah PD, Spurdle AB, Anton-Culver H, Ziogas A, Brewster W, Galitovskiy V, Chenevix-Trench G
مؤلفون مشاركون: Australian Cancer Study, Australian Ovarian Cancer Study Group
المصدر: British journal of cancer [Br J Cancer] 2009 Jan 27; Vol. 100 (2), pp. 412-20. Date of Electronic Publication: 2009 Jan 06.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Validation Study
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 2002- : London : Nature Publishing Group on behalf of Cancer Research UK
Original Publication: London, Lewis.
مواضيع طبية MeSH: Genetic Predisposition to Disease*, Cytochrome P-450 CYP3A/*genetics , DNA Ligases/*genetics , DNA-Binding Proteins/*genetics , Ovarian Neoplasms/*genetics , Polymorphism, Single Nucleotide/*genetics, Adult ; Aged ; Case-Control Studies ; Cohort Studies ; DNA Ligase ATP ; Female ; Genotype ; Heterozygote ; Homozygote ; Humans ; Middle Aged ; Neoplasm Invasiveness ; Ovarian Neoplasms/pathology ; Risk Factors
مستخلص: The search for genetic variants associated with ovarian cancer risk has focused on pathways including sex steroid hormones, DNA repair, and cell cycle control. The Ovarian Cancer Association Consortium (OCAC) identified 10 single-nucleotide polymorphisms (SNPs) in genes in these pathways, which had been genotyped by Consortium members and a pooled analysis of these data was conducted. Three of the 10 SNPs showed evidence of an association with ovarian cancer at P< or =0.10 in a log-additive model: rs2740574 in CYP3A4 (P=0.011), rs1805386 in LIG4 (P=0.007), and rs3218536 in XRCC2 (P=0.095). Additional genotyping in other OCAC studies was undertaken and only the variant in CYP3A4, rs2740574, continued to show an association in the replication data among homozygous carriers: OR(homozygous(hom))=2.50 (95% CI 0.54-11.57, P=0.24) with 1406 cases and 2827 controls. Overall, in the combined data the odds ratio was 2.81 among carriers of two copies of the minor allele (95% CI 1.20-6.56, P=0.017, p(het) across studies=0.42) with 1969 cases and 3491 controls. There was no association among heterozygous carriers. CYP3A4 encodes a key enzyme in oestrogen metabolism and our finding between rs2740574 and risk of ovarian cancer suggests that this pathway may be involved in ovarian carcinogenesis. Additional follow-up is warranted.
التعليقات: Erratum in: Br J Cancer. 2009 Nov 17;101(10):1805. Cunningham, J C [corrected to Cunningham, J M].
References: Lancet. 2007 May 19;369(9574):1703-10. (PMID: 17512855)
Nat Genet. 2001 Nov;29(3):306-9. (PMID: 11600885)
N Engl J Med. 2000 Jul 13;343(2):78-85. (PMID: 10891514)
Nature. 2007 Jun 28;447(7148):1087-93. (PMID: 17529967)
Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):209-16. (PMID: 11303589)
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):319-23. (PMID: 15734952)
Int J Cancer. 2008 Jan 1;122(1):170-6. (PMID: 17721999)
Future Oncol. 2006 Apr;2(2):257-74. (PMID: 16563094)
Clin Pharmacol Ther. 1999 Sep;66(3):288-94. (PMID: 10511065)
Int J Cancer. 2005 Nov 20;117(4):611-8. (PMID: 15924337)
Cancer Epidemiol Biomarkers Prev. 2003 Mar;12(3):187-90. (PMID: 12646505)
Br J Cancer. 2007 Aug 6;97(3):440-5. (PMID: 17622247)
Br J Obstet Gynaecol. 1998 May;105(5):493-9. (PMID: 9637117)
Int J Cancer. 2008 Jul 15;123(2):380-388. (PMID: 18431743)
Gynecol Oncol. 2002 Aug;86(2):124-8. (PMID: 12144816)
Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2536-43. (PMID: 16284375)
Biochem Biophys Res Commun. 1999 May 27;259(1):201-5. (PMID: 10334940)
Environ Mol Mutagen. 2003;42(4):299-305. (PMID: 14673875)
Cancer Res. 2007 Apr 1;67(7):3027-35. (PMID: 17409409)
Cancer Res. 2002 Jun 1;62(11):3058-62. (PMID: 12036914)
Science. 1994 Sep 30;265(5181):2037-48. (PMID: 8091226)
Nat Genet. 2003 Feb;33(2):177-82. (PMID: 12524541)
Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1373-6. (PMID: 11142424)
Br J Cancer. 2008 Jan 29;98(2):282-8. (PMID: 18219286)
Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2141-7. (PMID: 15598772)
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):481-9. (PMID: 17372243)
Science. 1996 Sep 13;273(5281):1516-7. (PMID: 8801636)
Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2557-65. (PMID: 18086758)
Am J Obstet Gynecol. 1998 Aug;179(2):403-10. (PMID: 9731846)
Pharmacogenetics. 2002 Jul;12(5):355-66. (PMID: 12142725)
Carcinogenesis. 2006 Nov;27(11):2235-42. (PMID: 16774946)
Am J Epidemiol. 2005 Mar 1;161(5):442-51. (PMID: 15718480)
Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):393-6. (PMID: 18268123)
Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):563-4. (PMID: 11352870)
Biochem Biophys Res Commun. 2005 Dec 9;338(1):299-305. (PMID: 16171783)
Int J Gynecol Cancer. 2003 Nov-Dec;13(6):785-90. (PMID: 14675315)
Int J Cancer. 2000 May 1;86(3):436-9. (PMID: 10760835)
Am J Epidemiol. 2004 Nov 1;160(9):825-41. (PMID: 15496535)
معلومات مُعتمدة: R01 CA087538 United States CA NCI NIH HHS; R01 CA095023 United States CA NCI NIH HHS; R01 CA058860 United States CA NCI NIH HHS; CA63464 United States CA NCI NIH HHS; CA17054 United States CA NCI NIH HHS; 2-R01-CA76016 United States CA NCI NIH HHS; R01 CA076016 United States CA NCI NIH HHS; CA61132 United States CA NCI NIH HHS; CA-92044 United States CA NCI NIH HHS; P01 CA017054 United States CA NCI NIH HHS; 5R01 CA054419 United States CA NCI NIH HHS; CA-58860 United States CA NCI NIH HHS; G0801875 United Kingdom MRC_ Medical Research Council; 10119 United Kingdom CRUK_ Cancer Research UK; T32 CA080416 United States CA NCI NIH HHS; CA66190 United States CA NCI NIH HHS; 10124 United Kingdom CRUK_ Cancer Research UK; R01 CA086888 United States CA NCI NIH HHS; 11021 United Kingdom CRUK_ Cancer Research UK; R01-CA86888 United States CA NCI NIH HHS; R01-CA-58598 United States CA NCI NIH HHS; N01-PC-67010 United States PC NCI NIH HHS; CA16056 United States CA NCI NIH HHS; N01-PC-35137 United States PC NCI NIH HHS; CA14089 United States CA NCI NIH HHS; R03-CA113148 United States CA NCI NIH HHS; R03 CA113148 United States CA NCI NIH HHS; R01 CA058598 United States CA NCI NIH HHS; R01-CA122443 United States CA NCI NIH HHS; K07 CA092044 United States CA NCI NIH HHS; N01-CN-55424 United States CN NCI NIH HHS; 5P50 CA105009 United States CA NCI NIH HHS; R01 CA054419 United States CA NCI NIH HHS; R01 CA122443 United States CA NCI NIH HHS
فهرسة مساهمة: Investigator: D Bowtell; G Chenevix-Trench; A Green; P Webb; A deFazio; D Gertig; N Traficante; S Moore; J Hung; S Fereday; K Harrap; T Sadkowsky; A Mellon; R Robertson; T Vanden Bergh; J Maidens; K Nattress; YE Chiew; A Stenlake; H Sullivan; B Alexander; P Ashover; S Brown; T Corrish; L Green; L Jackman; K Martin; B Ranieri; J White; V Jayde; L Bowes; P Mamers; T Schmidt; H Shirley; S Viduka; H Tran; S Bilic; L Glavinas; A Proietto; S Braye; G Otton; T Bonaventura; J Stewart; M Friedlander; D Bell; S Baron-Hay; A Ferrier; G Gard; D Nevell; B Young; C Camaris; R Crouch; L Edwards; N Hacker; D Marsden; G Robertson; P Beale; J Beith; J Carter; C Dalrymple; A Hamilton; R Houghton; P Russell; A Brand; R Jaworski; P Harnett; G Wain; A Crandon; M Cummings; K Horwood; A Obermair; D Wyld; J Nicklin; D Papadimos; L Perrin; B Ward; M Davy; C Hall; T Dodd; T Healy; K Pittman; D Henderson; S Hyde; J Miller; J Pierdes; P Blomfield; D Challis; R McIntosh; A Parker; B Brown; R Rome; D Allen; P Grant; S Hyde; R Laurie; M Robbie; D Healy; T Jobling; T Maniolitas; J McNealage; P Rogers; B Susil; A Veitch; J Constable; S Ping Tong; I Robinson; I Simpson; K Phillips; D Rischin; P Waring; M Loughrey; N O'Callaghan; B Murray; V Billson; S Galloway; J Pyman; M Quinn; I Hammond; A McCartney; Y Leung; I Haviv; D Purdie; D Whiteman; N Zeps
المشرفين على المادة: 0 (DNA-Binding Proteins)
0 (LIG4 protein, human)
0 (XRCC2 protein, human)
EC 1.14.14.1 (Cytochrome P-450 CYP3A)
EC 1.14.14.55 (CYP3A4 protein, human)
EC 6.5.1.- (DNA Ligases)
EC 6.5.1.1 (DNA Ligase ATP)
تواريخ الأحداث: Date Created: 20090108 Date Completed: 20090310 Latest Revision: 20231115
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC2634713
DOI: 10.1038/sj.bjc.6604820
PMID: 19127255
قاعدة البيانات: MEDLINE
الوصف
تدمد:1532-1827
DOI:10.1038/sj.bjc.6604820